darovasertib

Sponsor Ideaya Biosciences, INC. · listed as IDYA

READOUT Phase 2;Phase 3 Confidence: medium Source: clinicaltrials

darovasertib is a clinical-stage drug asset sponsored by Ideaya Biosciences, INC., listed as IDYA. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jan 15, 2027 (day precision, medium confidence), tied to trial NCT05987332. The asset is in Phase 2;Phase 3 and currently active not recruiting, studied in Metastatic Uveal Melanoma. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-01-15

As disclosedJan 15, 2027

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT05987332

PhasePHASE2;PHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorIDEAYA Biosciences

Listed asIDYA

Condition(s)Metastatic Uveal Melanoma

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More IDYA catalysts